A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods

M. D. Schluchter, A. F. Barker, R. G. Crystal, R. A. Robbins, J. M. Stocks, J. K. Stoller, M. C. Wu, Z. Bengali, C. E. Vreim, A. Rothgeb, G. L. Snider, K. Detre, H. Y. Reynolds, M. S. Tockman, J. Wittes, A. S. Buist, B. Burrows, A. Cohen, R. J. Fallat

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

The Registry of Patients with Severe Deficiency of Alpha1-Antitrypsin (AIAT) is a multicenter natural history study, with 37 participating clinical centers in the United States (36 centers) and Canada (1 center). The study has enrolled 1,129 individuals aged ≥18 years with severe deficiency of AIAT (serum level ≤11 μM), and will follow them longitudinally for up to 7 years, characterizing the clinical course of the disease, regardless of whether they are receiving augmentation therapy. Primary outcomes of interest are the yearly decline in FEV1 and mortality. This article describes the design and structure of the Registry.

Original languageEnglish (US)
Pages (from-to)1223-1232
Number of pages10
JournalCHEST
Volume106
Issue number4
DOIs
StatePublished - 1994

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods'. Together they form a unique fingerprint.

Cite this